- Home
- DXR vs CLNN Comparison
DXR vs CLNN Comparison
Compare DXR & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXR | CLNN |
|---|---|---|
| Founded | 1970 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.0M | 57.4M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DXR | CLNN |
|---|---|---|
| Price | $10.05 | $3.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $20.00 | ★ $32.20 |
| AVG Volume (30 Days) | 15.0K | ★ 88.6K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,446,345.00 | $200,000.00 |
| Revenue This Year | $44,489.33 | $24.70 |
| Revenue Next Year | $74.79 | $9,228.71 |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.56 | $3.20 |
| 52 Week High | $14.76 | $13.50 |
Technical Indicators
Market Signals| Indicator | DXR | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 39.18 | 26.52 |
| Support Level | $9.38 | N/A |
| Resistance Level | $10.99 | $4.70 |
| Average True Range (ATR) | 0.49 | 0.24 |
| MACD | -0.10 | -0.08 |
| Stochastic Oscillator | 5.24 | 0.79 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.